Circulating tumor cells (CTCs) are tumor cells that have sloughed off the primary tumor and
extravasate into and circulate in the blood. Understanding of the metastatic cascade of CTCs …

Growing evidence for intratumour heterogeneity informs us that single-site biopsies fall short
of revealing the complete genomic landscape of a tumour. With an expanding repertoire of …

Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real
time liquid biopsy. They are however present in a large background of hematopoietic cells …

Abstract The CellSearch® system (CS) enables standardized enrichment and enumeration
of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive “liquid …

In countries with the best cancer outcomes, approximately 60% of patients receive
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …

EpCAM expressing circulating tumor cells, detected by CellSearch, are predictive of short
survival in several cancers and may serve as a liquid biopsy to guide therapy. Here we …

In recent years, biotechnological breakthroughs have led to identification of complex and
unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling …

Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer
patients to provide information regarding the genetic landscape of the cancer. It is emerging …

Increasing evidence suggests that circulating tumour cells (CTCs) are responsible for
metastatic relapse and this has fuelled interest in their detection and quantification. Although …

In the last decades the approach to cancer patient management has been deeply
revolutionized. We are moving from a “one-fits-all” strategy to the “personalized medicine” …